RARE logo

Ultragenyx Pharmaceutical Inc. (RARE) Cash from operations

annual CFO:

-$414.19M+$60.62M(+12.77%)
December 31, 2024

Summary

  • As of today (September 16, 2025), RARE annual cash flow from operations is -$414.19 million, with the most recent change of +$60.62 million (+12.77%) on December 31, 2024.
  • During the last 3 years, RARE annual CFO has fallen by -$75.49 million (-22.29%).
  • RARE annual CFO is now -7010.52% below its all-time high of -$5.83 million, reached on December 31, 2011.

Performance

1-year change

+12.77%

3-year change

-22.29%

5-year change

-19.92%

15-year change

-63.17%

RARE Cash from operations Chart

Add series to chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Highlights

Sector rank

1.16%
RARE annual cash flow from operations is higher than 1.16% of companies in Healthcare sector

Range

All-time high

-$5.83M

3-year low

-$474.81M

Earnings dates

Last annual earnings report date

Dec 31, 2024
RARE previous annual earnings announcement was published on Dec 31, 2024

Next annual earnings report date

N/A
RARE next annual earnings announcement has not yet been scheduled

OtherRAREcash flow metrics

annual CFI

-$17.77M
RARE annual cash flow from investing activities is -$17.77 million

annual CFF

$399.24M
RARE annual cash flow from financing activities is $399.24 million

annual FCF

-$434.18M
RARE annual free cash flow is -$434.18 million

annual CAPEX

$19.99M
RARE annual capital expenditures is $19.99 million

quarterly CFO:

-$108.27M+$58.20M(+34.96%)
June 30, 2025

Summary

  • As of today (September 16, 2025), RARE quarterly cash flow from operations is -$108.27 million, with the most recent change of +$58.20 million (+34.96%) on June 30, 2025.
  • Over the past year, RARE quarterly CFO has dropped by -$31.31 million (-40.68%).
  • RARE quarterly CFO is now -223.95% below its all-time high of $87.35 million, reached on June 30, 2020.

Performance

3-month change

+34.96%

1-year change

-40.68%

3-year change

-40.15%

5-year change

-223.95%

RARE quarterly CFO Chart

Add series to chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Highlights

Sector rank

1.87%
RARE quarterly cash flow from operations is higher than 1.87% of companies in Healthcare sector

Range

All-time high

$87.35M
RARE quarterly cash flow from operations is currently -223.95% below its historical high of $87.35 million

3-year low

-$190.73M

Earnings dates

Last quarterly earnings report date

Jun 30, 2025
RARE previous earnings announcement was published on Jun 30, 2025

Next quarterly earnings report date

Nov 6, 2025
RARE next earnings announcement is scheduled for Nov 6, 2025

OtherRAREcash flow metrics

quarterly CFI

$71.17M
RARE quarterly cash flow from investing activities is $71.17 million

quarterly CFF

$83.65M
RARE quarterly cash flow from financing activities is $83.65 million

quarterly FCF

-$110.73M
RARE quarterly free cash flow is -$110.73 million

quarterly CAPEX

$2.46M
RARE quarterly capital expenditures is $2.46 million

TTM CFO:

-$421.25M-$31.31M(-8.03%)
June 30, 2025

Summary

  • As of today (September 16, 2025), RARE TTM cash flow from operations is -$421.25 million, with the most recent change of -$31.31 million (-8.03%) on June 30, 2025.
  • Over the past year, RARE TTM CFO has increased by +$48.22 million (+10.27%).
  • RARE TTM CFO is now -11942.48% below its all-time high of -$3.50 million, reached on September 1, 2012.

Performance

3-month change

-8.03%

1-year change

+10.27%

3-year change

-36.43%

5-year change

-150.23%

RARE TTM CFO Chart

Add series to chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Highlights

Sector rank

1.34%
RARE TTM cash flow from operations is higher than 1.34% of companies in Healthcare sector

Range

All-time high

-$3.50M

3-year low

-$508.67M

Earnings dates

Last quarterly earnings report date

Jun 30, 2025
RARE previous earnings announcement was published on Jun 30, 2025

Next quarterly earnings report date

Nov 6, 2025
RARE next earnings announcement is scheduled for Nov 6, 2025

OtherRAREcash flow metrics

TTM CFI

$25.30M
RARE TTM cash flow from investing activities is $25.30 million

TTM CFF

$91.17M
RARE TTM cash flow from financing activities is $91.17 million

TTM FCF

-$442.30M
RARE TTM free cash flow is -$442.30 million

TTM CAPEX

$21.05M
RARE TTM capital expenditures is $21.05 million

Cash from operations Formula

CFO = Net Income + Non Cash Expenses + Changes In Working Capital

RARE Cash from operations Trends

PeriodPeriodAnnualAnnualQuarterlyQuarterlyTTMTTM
1 y1 year+12.8%-40.7%+10.3%
3 y3 years-22.3%-40.1%-36.4%
5 y5 years-19.9%-223.9%-150.2%

RARE Cash from operations Highs & Lows

PeriodPeriodAnnual vs highAnnual vs highAnnual vs lowAnnual vs lowQuarter. vs highQuarter. vs highQuarter. vs lowQuarter. vs lowTTM vs highTTM vs highTTM vs lowTTM vs low
3 y3-year-22.3%+12.8%-61.6%+43.2%-36.4%+17.2%
5 y5-year-213.3%+12.8%-223.9%+43.2%-218.6%+17.2%
alltimeall time-7010.5%+12.8%-223.9%+43.2%<-9999.0%+17.2%

RARE Cash from operations History

DateAnnualQuarterlyTTM
Jun 2025
-
-$108.27M(-35.0%)
-$421.25M(+8.0%)
Mar 2025
-
-$166.47M(+109.4%)
-$389.94M(-5.9%)
Dec 2024
-$414.19M(-12.8%)
-$79.50M(+18.7%)
-$414.19M(-1.1%)
Sep 2024
-
-$67.00M(-13.0%)
-$418.59M(-10.8%)
Jun 2024
-
-$76.96M(-59.6%)
-$469.47M(-7.7%)
Mar 2024
-
-$190.73M(+127.3%)
-$508.67M(+7.1%)
Dec 2023
-$474.81M(+24.8%)
-$83.90M(-28.8%)
-$474.81M(-1.3%)
Sep 2023
-
-$117.87M(+1.5%)
-$481.24M(+4.9%)
Jun 2023
-
-$116.16M(-25.9%)
-$458.71M(+9.3%)
Mar 2023
-
-$156.87M(+73.6%)
-$419.81M(+10.3%)
Dec 2022
-$380.46M(+12.3%)
-$90.34M(-5.2%)
-$380.46M(+10.5%)
Sep 2022
-
-$95.34M(+23.4%)
-$344.47M(+11.6%)
Jun 2022
-
-$77.26M(-34.3%)
-$308.77M(+4.0%)
Mar 2022
-
-$117.52M(+116.3%)
-$296.87M(-12.3%)
Dec 2021
-$338.69M(+156.2%)
-$54.34M(-8.9%)
-$338.69M(-2.3%)
Sep 2021
-
-$59.65M(-8.7%)
-$346.80M(-0.7%)
Jun 2021
-
-$65.36M(-59.0%)
-$349.12M(+77.7%)
Mar 2021
-
-$159.35M(+155.1%)
-$196.41M(+48.6%)
Dec 2020
-$132.22M(-61.7%)
-$62.45M(+0.8%)
-$132.22M(-6.8%)
Sep 2020
-
-$61.97M(-170.9%)
-$141.81M(-15.8%)
Jun 2020
-
$87.35M(-191.8%)
-$168.35M(-51.2%)
Mar 2020
-
-$95.15M(+32.1%)
-$344.76M(-0.2%)
Dec 2019
-$345.38M(+18.9%)
-$72.04M(-18.6%)
-$345.38M(+4.9%)
Sep 2019
-
-$88.51M(-0.6%)
-$329.20M(+6.2%)
Jun 2019
-
-$89.06M(-7.0%)
-$309.85M(+4.4%)
Mar 2019
-
-$95.78M(+71.5%)
-$296.86M(+2.2%)
DateAnnualQuarterlyTTM
Dec 2018
-$290.57M(+14.5%)
-$55.85M(-19.2%)
-$290.57M(-8.2%)
Sep 2018
-
-$69.16M(-9.1%)
-$316.54M(+2.3%)
Jun 2018
-
-$76.08M(-15.0%)
-$309.37M(+9.7%)
Mar 2018
-
-$89.48M(+9.4%)
-$282.12M(+11.1%)
Dec 2017
-$253.84M(+57.7%)
-$81.82M(+32.0%)
-$253.84M(+15.5%)
Sep 2017
-
-$61.99M(+27.0%)
-$219.70M(+17.8%)
Jun 2017
-
-$48.82M(-20.2%)
-$186.45M(+5.2%)
Mar 2017
-
-$61.20M(+28.4%)
-$177.28M(+10.1%)
Dec 2016
-$160.97M(+51.9%)
-$47.68M(+65.9%)
-$160.97M(+4.7%)
Sep 2016
-
-$28.75M(-27.5%)
-$153.74M(-1.2%)
Jun 2016
-
-$39.66M(-11.7%)
-$155.59M(+16.8%)
Mar 2016
-
-$44.90M(+11.0%)
-$133.21M(+25.7%)
Dec 2015
-$105.98M(+137.4%)
-$40.44M(+32.2%)
-$105.98M(+32.0%)
Sep 2015
-
-$30.60M(+77.2%)
-$80.27M(+32.2%)
Jun 2015
-
-$17.27M(-2.2%)
-$60.70M(+12.5%)
Mar 2015
-
-$17.66M(+19.8%)
-$53.96M(+20.9%)
Dec 2014
-$44.63M(+43.1%)
-$14.74M(+33.6%)
-$44.63M(+12.5%)
Sep 2014
-
-$11.03M(+4.8%)
-$39.67M(+12.1%)
Jun 2014
-
-$10.53M(+26.3%)
-$35.38M(+6.4%)
Mar 2014
-
-$8.34M(-14.7%)
-$33.24M(+6.5%)
Dec 2013
-$31.20M(+149.5%)
-$9.77M(+44.8%)
-$31.20M(+24.1%)
Sep 2013
-
-$6.75M(-19.6%)
-$25.14M(+14.8%)
Jun 2013
-
-$8.39M(+33.3%)
-$21.89M(+62.1%)
Mar 2013
-
-$6.29M(+69.4%)
-$13.51M(+87.3%)
Dec 2012
-$12.50M(+114.7%)
-$3.71M(+6.2%)
-$7.21M(+106.2%)
Sep 2012
-
-$3.50M
-$3.50M
Dec 2011
-$5.83M
-
-

FAQ

  • What is Ultragenyx Pharmaceutical Inc. annual cash flow from operations?
  • What is the all time high annual CFO for Ultragenyx Pharmaceutical Inc.?
  • What is Ultragenyx Pharmaceutical Inc. annual CFO year-on-year change?
  • What is Ultragenyx Pharmaceutical Inc. quarterly cash flow from operations?
  • What is the all time high quarterly CFO for Ultragenyx Pharmaceutical Inc.?
  • What is Ultragenyx Pharmaceutical Inc. quarterly CFO year-on-year change?
  • What is Ultragenyx Pharmaceutical Inc. TTM cash flow from operations?
  • What is the all time high TTM CFO for Ultragenyx Pharmaceutical Inc.?
  • What is Ultragenyx Pharmaceutical Inc. TTM CFO year-on-year change?

What is Ultragenyx Pharmaceutical Inc. annual cash flow from operations?

The current annual CFO of RARE is -$414.19M

What is the all time high annual CFO for Ultragenyx Pharmaceutical Inc.?

Ultragenyx Pharmaceutical Inc. all-time high annual cash flow from operations is -$5.83M

What is Ultragenyx Pharmaceutical Inc. annual CFO year-on-year change?

Over the past year, RARE annual cash flow from operations has changed by +$60.62M (+12.77%)

What is Ultragenyx Pharmaceutical Inc. quarterly cash flow from operations?

The current quarterly CFO of RARE is -$108.27M

What is the all time high quarterly CFO for Ultragenyx Pharmaceutical Inc.?

Ultragenyx Pharmaceutical Inc. all-time high quarterly cash flow from operations is $87.35M

What is Ultragenyx Pharmaceutical Inc. quarterly CFO year-on-year change?

Over the past year, RARE quarterly cash flow from operations has changed by -$31.31M (-40.68%)

What is Ultragenyx Pharmaceutical Inc. TTM cash flow from operations?

The current TTM CFO of RARE is -$421.25M

What is the all time high TTM CFO for Ultragenyx Pharmaceutical Inc.?

Ultragenyx Pharmaceutical Inc. all-time high TTM cash flow from operations is -$3.50M

What is Ultragenyx Pharmaceutical Inc. TTM CFO year-on-year change?

Over the past year, RARE TTM cash flow from operations has changed by +$48.22M (+10.27%)
On this page